Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca receives CHMP backing for Brilique

AstraZeneca receives CHMP backing for Brilique

27th September 2010

AstraZeneca's European marketing authorisation application for the acute coronary syndromes (ACS) treatment Brilique has received the backing of a key healthcare committee.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the drug as a therapy for the prevention of atherothrombotic events among adult ACS sufferers.

This recommendation was based on positive data from clinical trials such as Plato, which demonstrated the superiority of Brilique compared to clopidogrel.

Following CHMP's decision, the European Commission is now expected to issue its final ruling on the drug within a few months.

Anders Ekblom, executive vice-president of global medicines development at AstraZeneca, said: "Despite advancements in the treatment of ACS, post-ACS death rates remain high. We are pleased with the CHMP's positive opinion and look forward to the European Commission decision for Brilique."

Last week, the company announced that its new thyroid cancer drug vandetanib has also been accepted for European regulatory review.ADNFCR-8000103-ID-800083272-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.